Canadian Agency for Drugs and Technologies in Health. (2020). Clinical review report: (Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc.) : indication : indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PEX) and immunosuppress. Canadian Agency for Drugs and Technologies in Health.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: (Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc.) : Indication : Indicated for the Treatment of Adults with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Combination with Plasma Exchange (PEX) and Immunosuppress. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2020.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: (Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc.) : Indication : Indicated for the Treatment of Adults with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in Combination with Plasma Exchange (PEX) and Immunosuppress. Canadian Agency for Drugs and Technologies in Health, 2020.
